Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury

Fig. 5

ZSTK474 reduces P-AKT and P-p70S6k protein levels. ZSTK474 suppresses phosphorylation of AKT and other downstream compounds. Western blots (a) and densitometry histograms (b–e) showing AKT, P-AKT, p70S6k, and P-p70S6k protein levels in ZSTK474-treated, control, and sham-treated mice following MCAO. P-AKT and P-p70S6k protein levels were dramatically decreased in the ZSTK474-treated group. Total AKT and p70S6k protein level, however, remained unchanged. Data in graphs are expressed as means ± SD; # P < 0.001, *P < 0.05 vs. control group; NS, not significant; n = 6

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094